Global Blood Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€201.51M - Cost of goods sold
€3.82M - Gross profit
€197.69M - SG&A expenses
€259.59M - R&D expenses
€194.85M - EBITDA
-€247.46M - D&A
€7.70M - EBIT
-€255.17M - Interest expenses
€21.20M - EBT
-€275.95M - Tax expenses
€4.09M - Net income
-€280.03M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€2.12M - Changes in working capital
-€12.74M - Operating cash flow
-€213.98M - Capex
€1.67M - Other investing cash flow
€0.00 - Net investing cash flow
-€335.31M - Total cash dividends paid
€0.00 - Issuance of common stock
€43.38M - Debt repayment
€0.00 - Other financing cash flow
€413.95M - Net financing cash flow
€413.95M - Foreign exchange effects
-€331.19K - Net change in cash
-€135.67M - Cash at end of period
€226.16M - Free cash flow
-€212.31M
Balance sheet
- Cash and cash equivalents
€224.07M - Cash and short-term investments
€443.72M - Total receivables
€25.54M - Inventory
€56.47M - Other current assets
€23.40M - Total current assets
€549.13M - Property, plant & equipment
€67.72M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€126.01M - Other non-current assets
€3.99M - Total non-current assets
€197.71M - Total assets
€746.84M - Accounts payable
€7.09M - Short-term debt
€5.25M - Other current liabilities
€67.54M - Total current liabilities
€79.87M - Long-term debt
€559.65M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€5.77M - Total non-current liabilities
€565.41M - Total liabilities
€645.29M - Common stock
€57.49K - Retained earnings
-€1.25B - Other equity
-€3.41M - Total equity
€101.55M - Total liabilities and shareholders' equity
€746.84M
Company information
- Market capitalization
€0.00 - Employees
457 - Enterprise Value
-€25.10M
Company ratios
- Gross margin
-
98.1% Much better than peer group: 48.9% - EBITDA margin
-
-122.8% Much better than peer group: -568.5% - EBIT margin
-
-126.6% Much better than peer group: -579.0% - EBT margin
-
-136.9% Much worse than peer group: 4,901.6% - Net margin
-
-139.0% Much better than peer group: -573.1% - ROE
-
-275.7% Much worse than peer group: 36.5% - ROA
-
-37.5% Much worse than peer group: 813.4% - Asset turnover
-
27.0% Much better than peer group: -685.5% - FCF margin
-
-107.0% Much better than peer group: -452.9% - FCF yield
0.0% - Efficiency ratio
222.8% - Net sales per employee
-
€440.94K - Net income per employee
-
-€612.76K